RESEARCH-USE BIOSIMILAR ANTIBODY

Tanezumab

Monoclonal antibody · IgG2

NGFIgG2RUO

Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia.

TARGETNGF
YMonoclonal antibody
CATALOGSC-BS-131
CATALOG NUMBERSC-BS-131
MOLECULAR WEIGHTApprox. 145.44 kDa
PRODUCT FORMATMonoclonal antibody

A research-use configuration for comparative antibody studies

Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia.

Tanezumab is a recombinant research-use antibody directed against NGF.

START A CONVERSATION

Tell us about your research goals.

For quotes, sample requests or technical support, start with your target and experimental context.

Contact StellaCyte
Tanezumab | StellaCyte